Introduction 57
Breast cancer (BC) is the leading cause of cancer-associated death (15%: 626,679 cases) 58 and the most commonly diagnosed cancer (24%: 2,088,849 cases) among women 59 worldwide 1 . BC is characterized by a complex interaction between environmental factors 60 and biological aspects, such as gene deregulation, hormone disruption or ethnicity [2] [3] [4] . 61
Despite subtype-specific treatment efforts, advanced BC with distant organ metastases is 62 considered incurable 2 . Therefore, a better understanding of BC molecular processes is still 63 of great interest to identify new therapeutic targets. 64
Current oncological research generates large-scale datasets that harbor essential aspects 65 of tumor biology. For instance, The Cancer Genome Atlas (TCGA), with over 2.5 petabytes 66 of data, has molecularly characterized over 20,000 patient samples covering 33 cancer 67 types [5] [6] [7] [8] [9] [10] . Also, The Cancer Dependency Map (DepMap) project, using loss-of-function 68 genetic screens, has identified essential genes for cancer proliferation and survival ex vivo 11-
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. Additionally, The Human Protein Atlas (HPA) constitutes a comprehensive resource to 70 explore the human proteome in healthy and tumor tissues [14] [15] [16] . Although these datasets 71 have completely redefined cancer drug development, diagnosis, and treatment, additional 72 key aspects of tumor biology remain to be discovered. In that respect, post-transcriptional 73 regulation of tumorigenesis represents an understudied aspect of cancer research 17 .
74
As key regulators of post-transcription, RNA binding proteins (RBPs) are particularly 75 relevant due to their implication in every post-transcriptional step of gene expression: RNA 76 splicing, transport, stability, translation, and localization. As a result, genomic alterations of 77 these proteins lead to dysfunctional cellular processes; indeed, RBPs are emerging as 78 critical regulators of tumorigenesis but only few have well-defined roles in BC [18] [19] [20] [21] [22] [23] [24] [25] [26] . To date, 79 1,393 RBPs have been experimentally identified from human RNA interactomes 27 . Despite 80 efforts to understand their role in cancer 28, 29 , an integrated analysis of the aforementioned 81 databases along with other in silico approaches is still missing in BC. To RBPs and BC genes were significantly higher than the one observed for non-cancer genes. 95
Interestingly, RBPs present a similar amount of genomic alterations than BC genes (Fig.  96   1A) , highlighting the putative role of RPBs in BC. 97
To obtain insights into how these proteins are altered in BC, we catalogued their genomic 98 alteration types. As shown in Fig. 1B and Supp. (Fig. 2D , Supp. Table 5 ). For instance, ARF1, the 126 most altered protein in stage IV (Fig. 2D) identified RBPs that may have a putative role in BC molecular pathways through PPIs. 143
Identification of differentially expressed RBPs in breast tumor tissues. 144
The Human Protein Atlas (HPA) constitutes 14-16 a major effort to address protein expression 145 in healthy and tumoral human tissues. We therefore identified RBPs having a differentially 146 protein expression profile in breast tumor tissues. To this end, we compared 147 immunohistochemical levels (not detected, low, medium and high) of 1212 available RBPs 148 between normal and cancerous breast tissues (Fig. 4 , Supp. Table 6 ). Most RBPs presented 149 common immunohistochemical levels between both breast tissues: not detected (n=130), 150 low (n=52), medium (n=366), and high (n=172) (Fig. 4A) . Moderate protein expression6 changes, defined by one variation level (e.g. not detected to low or medium to high) were 152 observed in 406 RBPs. 153
To identify RBPs with highly altered protein expression profiles in tumor tissues, we 154 categorized RBPs having a twofold variation level as upregulated or downregulated 155 compared with normal tissues; thus, we identified 24 upregulated and 62 downregulated 156 RBPs (Fig. 4A , Supp. Table 6 ). As expected, our approach revealed well-known BC 157 proteins, such as KPNA2 21 or G3BP2
22
, which validate our analysis. KPNA2 is highly 158 expressed in BC tissues (7 out of 12 tumor samples are classified as high) (Fig. 4B , Supp. 159 Table 6 ). On the contrary, G3BP2 expression is reduced in breast tumor tissues (Fig. 4B,  160 Supp. Table 6 ). We also observed two RBPs that have never been studied in BC: DARS2 161 (overexpressed) and SUPT6H (downregulated) (Fig. 4B , Supp. Table 6 ). 162
Exploring RBPs BC dependencies 163
Most RBPs present numerous genomic alterations ( 
portal/). Both initiatives 167
report loss-of-function screens performed in several human cancer cell lines [11] [12] [13] . 168 ranging from -1.3 to -1.5) the top ten essential RBPs for BC survival (Supp. (Fig. 5A ), being RAN, HSPE1, SNRNP200, SNRPD1, SARS, EEF2, 175 RPL37, CCT3, KPNB1, and RPL23 (mean dependency scores ranging from -1.5 to -1.8) the 176 top ten essential RBPs for tumor survival (Supp. Table 9 ). In toto, 207 essential RBPs were 177 identified by both computational methods ( Fig. 5A ; Supp. (HSPD1, UBE2M, SART3, USP36, GTPBP4, DHX33, and UPF1), 5 LumB (RPS21, GNL3L,7 ZNF207, AQR, and RPL17-C18orf32), 7 Her2 (DDX39B, NMT1, ISY1, DARS, HEATR1, 184 MAT2A, and SYF2), and 9 Basal (EIF3C, UTP20, TXN, NOP58, ALDOA, CCT2, NOP2, 185 DDX54, and PRMT1) (Fig. 5B) . 186
Unraveling putative BC RBPs 187
Cancer-related RBPs control hundreds of tumor mRNAs, interact with well-known cancer 188 driver proteins and appear to be highly altered in cancer genomic databases and tumor 189 tissues 32 . We therefore reasoned that integration of our previous analyses could narrow 190 down the identification of potential BC RBPs. 191
To this end, we first focused on RBPs having putative tumor progression profiles. Thus, we 192 Next, we focused on RBPs having putative tumor suppression profiles. In this concern, we 209 compared our afore made analyses as follows: 1) 348 RBPs belonging to the first quartile 210 of most genomically-altered RBPs concerning tumor suppression-related alterations (mRNA 211 downregulation, deep deletions, gene mutations or fusions); 2) All 398 RBPs presenting 212
PPIs with well-known BC proteins (Supp. The results of this research revealed for the first time that RBPs are equally altered than 232 well-known BC proteins (Fig. 1A) ; this was expected since many RBPs are highly altered 233 across cancer types 29 and have been in silico linked to cancer-related cellular processes 82 .
234
Contrary to a predominant mRNA downregulation pattern across cancers 29 , we found that 235 most RBPs genomic alterations in BC are mRNA upregulation (68.7%) and amplification 236 (15.4%) (Fig. 1B) . This probably will increase RBPs cellular concentrations leading to 237 dysfunctional post-transcriptional processes. 238
To determine how many RBPs have been previously studied in BC, we next analyzed the 239 most recent catalog of cancer driver genes: NCG6
30
. Only 14 RBPs have been catalogued 240 as BC driver genes ( Fig. 2A) . This indicates that RBPs have been poorly investigated in 241 breast carcinogenesis. Thus, to identify new putative BC RBPs, we first explored their 242 genomic alteration profiles associated with tumor progression or suppression ( , validating our strategy (Table 1) . On the 245 contrary, our strategy revealed RBPs that have not been previously associated with 246 tumorigenesis, and yet they are highly altered in BC (e.g. TFB2M, C1ORF131 or DDX19A)9 (Table 1) . Interestingly, the most altered RBP (MRPL13) in our analysis has never been 248 studied in cancer. MRPL13, along with other highly altered RBPs (Table 1) , has only shown 249 to interact with ESR2, a tumor suppressor in breast and other cancer types 33 . This 250 observation led us to investigate how many RBPs interact with ESR2; strikingly, we found 251 that 30% of all RBPs interact with this receptor 33 . ESR2 could probably exert its suppressive 252 activity through post-transcriptional mechanisms implicating several RBPs; nevertheless, 253 more research is needed to understand this observation. 254
Second, to further characterize RBPs associated with BC subtypes and staging, we hence 255 analyzed RBPs genomic alterations (Fig. 2C-D) . Interestingly, RBPs genomic alterations 256 gradually increased from Normal to Basal subtype (Fig. 2C) , i.e. from low to a high 257 proliferative stage 2 . Concordantly, metastasized tumors (stage IV) showed high frequencies 258 of RBPs genomic alterations compared to non-metastasized samples (stage I to III) (Fig.  259   2D) . Therefore, it seems that RBPs are acting as BC progressors rather than suppressors, 260 which agrees with their genomic alteration profiles (Fig. 1B) . This analysis also revealed 261 highly altered RBPs per subtype or staging ( Fig. 2C-D ; Supp. Table 4 Interaction networks have been shown to be useful for identifying key tumoral proteins 37 . In 269 this regard, by analyzing PPIs between RBPs and well-known BC proteins, we identified 270 SF3B1 and CDC5L at the core of two main networks (Fig. 3) . While SF3B1 has been 271 previously implicated in BC 84 , CDC5L, which interacts with 14 BC proteins, has not been 272 studied in this malignancy. However, CDC5L has been related with other cancer types, such 273 as osteosarcoma 85 and prostate cancer 86 , showing its possible role in breast carcinogenesis. 274
Next, we exploited the HPA database [14] [15] [16] to identify differentially expressed RBPs in tumor 275 breast tissues. We found 24 upregulated and 62 downregulated RBPs compared with 276 normal tissues. As expected, our approach revealed well-known BC proteins. For instance, 277 KPNA2 which has been known to enhance BC metastasis ex vivo 21 , is highly expressed in 278 BC tissues (7 out of 12 tumor samples are classified as high) (Fig. 4B , Supp. Table 6 ). On 279 the contrary, G3BP2 expression is reduced in tumoral breast tissues (Fig. 4B , Supp. Table  280 6); accordingly, loss of G3BP2 enhances tumor invasion and metastasis in vivo 22 . 281
Interestingly, DARS2 which has never been related with BC is upregulated in our analysis 282 (10 out 12 tumor samples are classified as high) (Fig. 4B , Supp. Table 6 ) and has been 283 associated with hepatocarcinogenesis progression 87 , showing its putative implication in BC. 284
In addition, SUPT6H protein expression is diminished in breast tumoral tissues (Fig. 4B,  285 Supp. Table 6) . In toto, we identified 207 essential RBPs for tumor 290 survival. This was expected since RBPs control every aspect of RNA metabolism. However, 291 only 59 were characterized as essential by both computational methods ( Fig. 5A ; Supp. 292 Table 8 -9). Although CERES 11 and DEMETER2 12,13 did not tested all human RBPs, 293 therapeutic posttranscriptional BC research could therefore be focused on these 59 RBPs. 294
However, more research is needed to deeply understand their carcinogenic roles. Also, we 295 revealed essential RBPs per BC molecular subtype (Fig. 5B ) that could be analyzed to better 296 understand subtype-related posttranscriptional processes. 297
In extending the scope of our previous analyses, we finally reasoned that integration of all 298 databases examined could narrow down the identification of potential BC RBPs. First, we 299 focused on RBPs having putative tumor progression profiles unraveling 19 RBPs with 300 tumorigenic characteristics according to our analyses (Fig. 5A) . As expected, most of them 301 (13 out 19) have been described as BC tumor progressors, controlling different cellular 302 processes: migration, invasion, and metastasis [43] [44] [45] [46] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] . Interestingly, NSF, SF3A3, PRPF3, 303 and MAGOHB have never been studied in cancer. While on the other hand, PUF60 has 304 been associated with colon and non-small cell lung cancer 47, 48 and PLEC has been shown 305 to promote migration and invasion of neck squamous cell carcinoma Table S1 ). 333 Genomic analysis. Genomic alterations of RBPs, non-cancer and BC genes were analyzed 334 through the cBioPortal (http://www.cbioportal.org/) 91,92 using the Breast Invasive Carcinoma 335 (TCGA, PanCancer Atlas) database (n = 994 complete samples) [5] [6] [7] [8] [9] [10] . To compare the 336 aforementioned gene sets, genomic alterations per protein were corrected by the number of 337 genes or individuals (Fig. 1A, Fig. 2C and D) . A Mann-Whitney U test was used to compare 338 genomic alterations between gene sets or clinical characteristics. 339 Network construction. Experimental and database interactions (Figure 3 and Table S3 ) 340 between RBPs (n=1392) and BC proteins (n=171) 30 , having an interaction score of 0.9 341 (highest confidence), were extracted from STRING database 93 [14] [15] [16] . Expression levels of normal tissues were taken from 346 glandular cells, while a consensus level was manually generated for BC tissues (Table S6) 
